Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (21 quarters reported)
$466M in Q4 2014 → — now. Hover for any quarter.
As reported for the quarter ended December 31, 2019. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| N N/a | NaN% | New | 0 | — |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended December 31, 2019 · filed January 27, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Theravance Biopharma Inc | Exited | −11,350,719 | −$221M | — |
| Evofem Biosciences Inc | Exited | −12,496,222 | −$63M | — |
| Autolus Therapeutics PLC | Exited | −2,095,127 | −$26M | — |
| N N/a | New | +0 | — | — |
quarter ended September 30, 2019 · filed November 08, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Autolus Therapeutics PLC | Trimmed | −9,499,107 | −$118M | 8.4% |
| Prothena Corp PLC | Exited | −8,773,790 | −$92.7M | — |
| Nucana PLC | Exited | −2,118,000 | −$22M | — |
| Theravance Biopharma Inc | Trimmed | −809,261 | −$15.8M | 71.3% |
| Evofem Biosciences Inc | Trimmed | −1,237,613 | −$6.24M | 20.3% |
quarter ended June 30, 2019 · filed November 12, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Agios Pharmaceuticals Inc | Exited | −2,214,459 | −$149M | — |
| Alkermes PLC | Exited | −2,639,676 | −$96.3M | — |
| Biogen Inc | Exited | −300,040 | −$70.9M | — |
| Prothena Corp PLC | Trimmed | −3,150,824 | −$33.3M | 15.7% |
| Theravance Biopharma Inc | Trimmed | −1,219,999 | −$19.9M | 33.6% |
| Evofem Biosciences Inc | Added | +2,190,107 | +$14.5M | 15.4% |
| Nucana PLC | Trimmed | −1,112,999 | −$11.6M | 3.7% |
| Autolus Therapeutics PLC | Trimmed | −447,185 | −$7.2M | 31.6% |
quarter ended March 31, 2019 · filed August 22, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Theravance Biopharma Inc | Added | +1,063,450 | +$24.1M | 24.5% |
| Nucana PLC | Added | +1,365,999 | +$23.2M | 4.4% |
| NT Nightstar Therapeutics PLC | Exited | −1,921,315 | −$22.1M | — |
| Biogen Inc | Added | +73,476 | +$17.4M | 5.7% |
| Agios Pharmaceuticals Inc | Added | +237,000 | +$16M | 12.1% |
| Evofem Biosciences Inc | Added | +1,950,531 | +$6.83M | 3.3% |
| Autolus Therapeutics PLC | Added | +116,000 | +$3.65M | 30.6% |
quarter ended December 31, 2018 · filed August 22, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Autolus Therapeutics PLC | Added | +1,099,500 | +$36.1M | 33.9% |
| Agios Pharmaceuticals Inc | Added | +660,000 | +$30.4M | 7.9% |
| Biogen Inc | Trimmed | −68,000 | −$20.5M | 5.9% |
| Nucana PLC | Added | +1,293,000 | +$18.7M | 2.3% |
| Theravance Biopharma Inc | Added | +621,650 | +$15.9M | 27.3% |
| NT Nightstar Therapeutics PLC | Added | +1,239,206 | +$14.3M | 1.9% |
| Alkermes PLC | Trimmed | −20,000 | −$590K | 6.7% |
quarter ended September 30, 2018 · filed August 22, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Autolus Therapeutics PLC | Added | +9,234,176 | +$283M | 26.4% |
| Alkermes PLC | Trimmed | −2,057,334 | −$87.3M | 9.0% |
| Agios Pharmaceuticals Inc | Added | +927,459 | +$71.5M | 8.1% |
| Theravance Biopharma Inc | Added | +481,000 | +$15.7M | 30.4% |
| NT Nightstar Therapeutics PLC | Added | +368,109 | +$7.52M | 1.1% |
| Altria Group Inc | Exited | −118,000 | −$6.7M | — |
| Biogen Inc | Added | +15,000 | +$5.3M | 8.3% |
| Nucana PLC | Added | +152,000 | +$3.79M | 1.1% |
quarter ended June 30, 2018 · filed August 09, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Autolus Therapeutics PLC | New | +1,591,743 | +$42.6M | 5.2% |
| Agios Pharmaceuticals Inc | New | +390,000 | +$32.8M | 4.0% |
| Alkermes PLC | Trimmed | −553,418 | −$22.8M | 23.5% |
| Theravance Biopharma Inc | Added | +315,000 | +$7.14M | 30.8% |
| Altria Group Inc | New | +118,000 | +$6.7M | 0.8% |
| Evofem Biosciences Inc | Added | +2,127,659 | +$5.77M | 3.2% |
| Prothena Corp PLC | Added | +367,000 | +$5.35M | 21.1% |
| NT Nightstar Therapeutics PLC | New | +314,000 | +$5.02M | 0.6% |
| Nucana PLC | Added | +90,000 | +$1.71M | 1.0% |
quarter ended March 31, 2018 · filed August 09, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Alkermes PLC | Trimmed | −2,315,255 | −$134M | 27.2% |
| Gilead Sciences Inc | Exited | −1,579,353 | −$113M | — |
| B Bioverativ Inc | Exited | −1,948,325 | −$105M | — |
| Evofem Biosciences Inc | New | +7,465,538 | +$47.4M | 4.2% |
| Biogen Inc | Trimmed | −91,000 | −$24.9M | 6.8% |
| Nucana PLC | New | +330,000 | +$6.24M | 0.6% |
| Theravance Biopharma Inc | Added | +151,771 | +$3.68M | 23.5% |
| Prothena Corp PLC | Added | +29,000 | +$1.06M | 37.7% |
Loading...
